Daxor Co. (NASDAQ:DXR – Get Free Report) was the recipient of a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 14,900 shares, an increase of 144.3% from the November 15th total of 6,100 shares. Currently, 0.7% of the company’s stock are sold short. Based on an average daily trading volume, of 16,600 shares, the short-interest ratio is currently 0.9 days.
Analyst Upgrades and Downgrades
Separately, Ascendiant Capital Markets boosted their price objective on Daxor from $24.50 to $24.75 and gave the stock a “buy” rating in a research report on Monday, September 9th.
Get Our Latest Report on Daxor
Daxor Stock Up 0.1 %
Hedge Funds Weigh In On Daxor
A hedge fund recently raised its stake in Daxor stock. Keyes Stange & Wooten Wealth Management LLC increased its position in shares of Daxor Co. (NASDAQ:DXR – Free Report) by 34.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 14,612 shares of the company’s stock after acquiring an additional 3,771 shares during the period. Keyes Stange & Wooten Wealth Management LLC owned approximately 0.30% of Daxor worth $126,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 1.34% of the company’s stock.
About Daxor
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.
Featured Articles
- Five stocks we like better than Daxor
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- The Great CPU Race: AMD and Intel Battle for Dominance
- Stock Sentiment Analysis: How it Works
- GameStop Turns a Profit: So What? It’s Still Not Worth Investing
- Earnings Per Share Calculator: How to Calculate EPS
- C3.ai Stock Surges on Strong Sales Despite Profit Concerns
Receive News & Ratings for Daxor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor and related companies with MarketBeat.com's FREE daily email newsletter.